Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant? - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Hematology/Oncology Clinics of North America Année : 2016

Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant?

Résumé

Major progress in the understanding of diffuse large B-cell lymphoma (DLBCL) biology has been made in the last decade. Many specific compounds have now entered early phase clinical trials. However, further efforts are needed to find an accurate, fast, reproducible, and affordable technique to translate DLBCL subtype determination by gene expression profiles into clinical application. This article discusses the advantages and drawbacks of the currently available techniques of DLBCL subtype determination as well as important prognostic implications related to the cell of origin. Furthermore, the article provides a schematic description of how molecularly defined DLBCL subtypes could guide tailored therapy

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-01800003 , version 1 (25-05-2018)

Identifiants

Citer

Pierre Sujobert, Gilles Salles, Emmanuel Bachy. Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant?. Hematology/Oncology Clinics of North America, 2016, 30 (6), pp.1163-1177. ⟨10.1016/j.hoc.2016.07.001⟩. ⟨hal-01800003⟩
34 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More